Analytica-2015: Quantitative dried blood spot analyses: An aid to medicine optimization for heart disease patients- Dennis Bernieh - De Montfort University

Dennis Bernieh  
De Montfort University, UK

Over 355 million solutions were administered for cardiovascular infections in the UK in 2013. Half of these, costing the NHS £2.3 billion, were squandered in light of the fact that patients don't accept their prescriptions as endorsed. A technique utilizing dried blood spot (DBS) test assortment followed by fluid chromatography-high goals mass spectrometry (LC-HRMS) was created and approved for measurement of eleven normally UK endorsed cardiovascular medications: amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, doxazosin, lisinopril, losartan, ramipril, simvastatin and valsartan. Hence prescription effectiveness, adherence or medication/tranquilize associations can be evaluated from reference pharmacokinetic information.

Methods: For the readiness of DBS adjustment tests entire blood was spiked with eleven objective analytes to create 30 μl blood spots on example cards. 8 mm circle was punched out and separated with methanol: water (70:30 v/v) containing the inner norm, atenolol D7. Chromatography investigation was performed utilizing slope elution with a run time of 2.5 min. MS location was completed in electrospray positive particle mode for all objective analytes and inner norm.

Results: The LC-HRMS strategy indicated great linearity and the exactness (relative mistake) and accuracy (coefficient of variety) values were inside the pre-characterized cutoff points of ≤15% at all tried fixations for eight of the objective medications. Medication recoveries from spiked blood spots were ≥ 82% for atenolol, bisoprolol, diltiazem, doxazosin, losartan, ramipril and valsartan. Results from volunteers were inside expected levels aside from where raised levels demonstrated a perceived medication/tranquilize connection.

Conclusion: Quantitative DBS examinations can be utilized as a way to streamline medicine for heart disease patients. Through the introduction of advanced analytical techniques and improved throughput, the scope of dried blood spot testing utilising mass spectrometric methods, has broadly expanded. Clinicians and researchers have become very enthusiastic about the potential applications of dried blood spot based mass spectrometric applications. Analysts on the other hand face challenges of sensitivity, reproducibility and overall accuracy of dried blood spot quantification. In this review, we aim to bring together these two facets to discuss the advantages and current challenges of non-newborn screening applications of dried blood spot quantification by mass spectrometry.

Biography

Dennis Bernieh is a PhD student in the Leicester School of Pharmacy at De Montfort University. His research interests lie in drug treatment optimization and dried blood spot analysis. He is researching into the quantification of therapeutic drugs from dried blood spots based on LC-MS and LC-MS/MS studies for medicine optimization. Prior to starting his PhD studies, he was a KTP Research Associate working for the Department of Chemistry of the University of Hull-UK, and Cobalt Light Systems Ltd in Oxfordshire UK.

Email: dennis.bernieh@email.dmu.ac.uk